Small Molecules
9 February 2015
Trevena Announces Positive Results from Phase 1 Multiple Ascending Dose Study of TRV734 for Moderate to Severe Acute and Chronic Pain5 February 2015
Akaal Pharma Announces Positive Results from Phase 1 Clinical Study of Novel Topical AKP-11 for the Treatment of Psoriasis5 February 2015
Albireo Announces Initiation of a Phase II Trial for A4250, the Company’s Lead Compound for Cholestatic Liver Diseases and NASH5 February 2015
Ironwood Reports Positive Top-Line Data from Exploratory Phase IIa Trial Of IW-3718 in Refractory Gastroesophageal Reflux Disease4 February 2015
Pierre Fabre Pharmaceuticals Announce Initiation of Phase IIa Clinical Trial Program for F17464 in Schizophrenia4 February 2015
Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin4 February 2015
Genentech’s Phase III Study of Gazyva® Showed Significant Benefit in Refractory Indolent Non-Hodgkin’s Lymphoma3 February 2015
InMed Expands Pipeline with Initiation of Program Targeting Epidermolysis bullosa simplex (EBS)3 February 2015
U.S. FDA Grants Priority Review for YONDELIS® (trabectedin) for the Treatment of Patients with Advanced Soft Tissue Sarcoma2 February 2015
AB Science: Positive Phase 2 Clinical Study Data of Masitinib in Second-Line Metastatic Stomach Cancer2 February 2015
Bionomics Begins Phase 1b Study With Anxiety Drug Bnc2102 February 2015
U.S. FDA approves first-in-class Glyxambi® (empagliflozin/linagliptin) tablets for adults with type 2 diabetesNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports